pHM6-alphasynuclein-A53T Citations (11)

Originally described in: Alpha-synuclein overexpression promotes aggregation of mutant huntingtin.
Furlong RA, Narain Y, Rankin J, Wyttenbach A, Rubinsztein DC Biochem J. 2000 Mar 15;346 Pt 3:577-81. PubMed Journal

---

Articles Citing pHM6-alphasynuclein-A53T

Articles
Phosphorylation at serine 31 targets tyrosine hydroxylase to vesicles for transport along microtubules. Jorge-Finnigan A, Kleppe R, Jung-Kc K, Ying M, Marie M, Rios-Mondragon I, Salvatore MF, Saraste J, Martinez A. J Biol Chem. 2017 Jun 21. pii: jbc.M116.762344. doi: 10.1074/jbc.M116.762344. PubMed
Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T alpha-synuclein model of Parkinson's disease. Chen J, Ren Y, Gui C, Zhao M, Wu X, Mao K, Li W, Zou F. Cell Death Dis. 2018 Jun 13;9(6):700. doi: 10.1038/s41419-018-0722-7. PubMed
Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models. Shaltouki A, Hsieh CH, Kim MJ, Wang X. Acta Neuropathol. 2018 Oct;136(4):607-620. doi: 10.1007/s00401-018-1873-4. Epub 2018 Jun 9. PubMed
Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity. Jan A, Jansonius B, Delaidelli A, Bhanshali F, An YA, Ferreira N, Smits LM, Negri GL, Schwamborn JC, Jensen PH, Mackenzie IR, Taubert S, Sorensen PH. Acta Neuropathol Commun. 2018 Jul 2;6(1):54. doi: 10.1186/s40478-018-0554-9. PubMed
p38 MAPK-DRP1 signaling is involved in mitochondrial dysfunction and cell death in mutant A53T alpha-synuclein model of Parkinson's disease. Gui C, Ren Y, Chen J, Wu X, Mao K, Li H, Yu H, Zou F, Li W. Toxicol Appl Pharmacol. 2020 Feb 1;388:114874. doi: 10.1016/j.taap.2019.114874. Epub 2019 Dec 24. PubMed
Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes alpha-synuclein degradation via transcription factor EB-dependent autophagy in mutant alpha-synucleinA53T model of Parkinson's disease. Mao K, Chen J, Yu H, Li H, Ren Y, Wu X, Wen Y, Zou F, Li W. Aging Cell. 2020 Jun;19(6):e13163. doi: 10.1111/acel.13163. Epub 2020 May 31. PubMed
Characterization of Small-Molecule-Induced Changes in Parkinson's-Related Trafficking via the Nedd4 Ubiquitin Signaling Cascade. Hatstat AK, Ahrendt HD, Foster MW, Mayne L, Moseley MA, Englander SW, McCafferty DG. Cell Chem Biol. 2021 Jan 21;28(1):14-25.e9. doi: 10.1016/j.chembiol.2020.10.008. Epub 2020 Nov 10. PubMed
O-GlcNAcylation regulates dopamine neuron function, survival and degeneration in Parkinson disease. Lee BE, Kim HY, Kim HJ, Jeong H, Kim BG, Lee HE, Lee J, Kim HB, Lee SE, Yang YR, Yi EC, Hanover JA, Myung K, Suh PG, Kwon T, Kim JI. Brain. 2020 Dec 1;143(12):3699-3716. doi: 10.1093/brain/awaa320. PubMed
alpha-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response. Delaidelli A, Richner M, Jiang L, van der Laan A, Bergholdt Jul Christiansen I, Ferreira N, Nyengaard JR, Vaegter CB, Jensen PH, Mackenzie IR, Sorensen PH, Jan A. Acta Neuropathol Commun. 2021 Jun 6;9(1):105. doi: 10.1186/s40478-021-01209-3. PubMed
Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration. Wang C, Lau CY, Ma F, Zheng C. Proc Natl Acad Sci U S A. 2021 Aug 24;118(34). pii: 2106504118. doi: 10.1073/pnas.2106504118. PubMed
p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease. Chen J, Mao K, Yu H, Wen Y, She H, Zhang H, Liu L, Li M, Li W, Zou F. J Neuroinflammation. 2021 Dec 20;18(1):295. doi: 10.1186/s12974-021-02349-y. PubMed

If you have published an article using this material, please email us at to have your article added to this page.